Keyword
in
Collection
Date
to
Download Folder

0 items

Houston Voice, June 3, 2005
File 014
Citation
MLA
APA
Chicago/Turabian
Houston Voice, June 3, 2005 - File 014. 2005-06-03. University of Houston Libraries. University of Houston Digital Library. Web. December 16, 2017. http://digital.lib.uh.edu/collection/montrose/item/1051/show/1039.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(2005-06-03). Houston Voice, June 3, 2005 - File 014. Montrose Voice. University of Houston Libraries. Retrieved from http://digital.lib.uh.edu/collection/montrose/item/1051/show/1039

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, June 3, 2005 - File 014, 2005-06-03, Montrose Voice, University of Houston Libraries, accessed December 16, 2017, http://digital.lib.uh.edu/collection/montrose/item/1051/show/1039.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, June 3, 2005
Contributor
  • Crain, Chris
  • Fisher, Binnie
Publisher Window Media
Date June 3, 2005
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Rights In Copyright: This item is protected by copyright. Copyright to this resource is held by the creator or current rights holder, and the resource is provided here for educational purposes. It may not be reproduced or distributed in any format without permission of the copyright owner. Users assume full responsibility for any infringement of copyright or related rights.
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 014
Transcript HOUSTON VOICE www.houstonvoice.com JUNE 3,2005 13 INDICATION: Reyataz (atazanavir sulfate) is a prescription medicine used in combination with other medicines to treat people who are infected with the human immunodeficiency virus (HIV). Reyataz has been studied in 48-week trials in both patients who have taken or have never taken anti-HIV medicines. Reyataz does not cure HIV or help prevent passing HIV to others. IMPORTANT SAFETY INFORMATION: Do not take Reyataz if you are taking the following medicines: ergot medicines, Versed', Halcion', Orap', Propulsid', Camptosar', Crixivan', Mevacor', Zocor', rifampin, St. John's wort, AcipHex', Nexium", Prevacid", Prilosec" or Protonix'. Do not use Viagra*, Levitra", Cialis', or Vfend' while you are taking Reyataz without first speaking with your healthcare provider. This list of medicines is not complete. Discuss all prescription and non-prescription medicines, vitamin and herbal supplements, or other health preparations you are taking or plan to take with your healthcare provider. Tell your healthcare provider right away if you have any side effects or conditions, including the following: • A change in the way your heart beats may occur and could be a symptom of a heart problem. • Diabetes and high blood sugar may occur in patients taking protease inhibitor medicines like Reyataz. • Yellowing of the skin and/or eyes may occur due to increases in bilirubin levels in the blood (bilirubin is made by the liver). • Rash (redness and itching) sometimes occurs in patients taking Reyataz, most often in the first few weeks after the medicine is started, and usually goes away within two weeks with no change in treatment. • If you have liver disease, including hepatitis B or C, your liver disease may get worse when you take anti-HIV medicines like Reyataz. • Some patients with hemophilia have increased bleeding problems with protease inhibitor medicines like Reyataz. Changes in body fat have been seen in some patients taking anti-HIV medicines.The cause and long-term effects are not known at this time. Common side effects of Reyataz taken with other anti-HIV medicines include: nausea, headache, stomach pain, vomiting, diarrhea, depression, fever, dizziness, trouble sleeping, numbness, and tingling or burning of hands or feet. You should take Reyataz once daily with food (a meal or snack). You should take Reyataz and your other anti-HIV medicines exactly as instructed by your healthcare provider. Please see important information about REYATAZ on the next page. Omm Daffy REYATAZ tis^MMitmW ^J -wM IM-^P tmWfG fQitf T-*Cd-M ♦ Cam hmmf mvmn yotm ifcjl land to 4> TwwpmttDttmmm**mwyrWi»<» 1Uitli*it«*i**'iNtt*flnKti^^ (ttl'llsitlttirjomttlirtW'iialll HWflWiiKomlilriWmitl^ »aplt*>**M**w^ cmrs-di^JiSfiwtfllWti*^^ ■^mmmMmmrdmttmcm (atazanavir sulfate) SgSIS RMS/V»n>Iogy- RIYATAZ is i registered trademark of Bristol-Myers Squibb Company © 2004 Bristol-Myers Squibb Company, Princeton, Nl 085*43
File Name uhlib_31485329_n1284_013.jpg